BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//The BioCalendar - ECPv6.16.5//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://thebiocalendar.com
X-WR-CALDESC:Events for The BioCalendar
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20250309T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20251102T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20260308T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20261101T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20270314T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20271107T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260602T110000
DTEND;TZID=America/Los_Angeles:20260602T120000
DTSTAMP:20260522T082937Z
CREATED:20260505T144223Z
LAST-MODIFIED:20260522T082937Z
UID:10362-1780398000-1780401600@thebiocalendar.com
SUMMARY:Advancing Next Gen Antibodies and ADCs: From AI Driven Cell Line Development to Integrated Manufacturing
DESCRIPTION:Antibody-drug conjugate (ADC) development continues to evolve\, with increased molecular complexity leading to new opportunities and challenges across design\, development\, and manufacturing. The industry is advancing novel technologies to support these next-generation antibody therapies and is adopting workflows better suited to their unique development considerations. \nIn this webinar\, we will examine how development teams address these challenges through more integrated and data driven CMC strategies. We will focus on how AI driven cell line development is enabling faster clone selection\, improved productivity\, and earlier insight into product quality risks. We will cover key considerations from early process development through scale up and manufacturing and how these approaches enable consistency\, efficiency\, and commercialization readiness\, with insights applicable to emerging formats such as multi-specific antibodies and ADCs. \nThe session will conclude with perspectives on the future of ADC manufacturing and bioproduction for complex molecules. It will highlight how AI\, bioprocess integration\, and digital connectivity may enable more predictive development and integrated manufacturing platforms. Attendees will gain insight into how emerging technologies can help de risk next generation programs while accelerating timelines and supporting long term manufacturing readiness. \nKey Learning Objectives\n~ Understand how increasing molecular complexity is reshaping CMC requirements across the development and manufacturing lifecycle\n~ Learn how AI driven cell line development and robust manufacturing strategies are enabling more efficient and robust development and control of critical quality attributes\n~ Explore future manufacturing paradigms for antibody-based therapeutics
URL:https://thebiocalendar.com/event/advancing-next-gen-antibodies-and-adcs-from-ai-driven-cell-line-development-to-integrated-manufacturing/
LOCATION:Online webinar
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/05/06-02-26-Cytiva-LinkedIn-1280x720-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260602T110000
DTEND;TZID=America/Los_Angeles:20260602T120000
DTSTAMP:20260522T082910Z
CREATED:20260506T180207Z
LAST-MODIFIED:20260522T082910Z
UID:10387-1780398000-1780401600@thebiocalendar.com
SUMMARY:Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV Capsids
DESCRIPTION:Join Viralgen\, Genosafe and DarkHorse Consulting as they discuss their experience with novel capsid manufacturing\, analytical testing and regulatory guidance. \nKey learning objectives:\n– Ways to address the complexity of novel capsid manufacturing\n– Approaches to consider with the analytical testing of novel capsids\n– Regulatory considerations around novel capsids
URL:https://thebiocalendar.com/event/addressing-manufacturing-and-characterization-challenges-and-opportunities-with-novel-aav-capsids/
LOCATION:Online webinar
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/05/06-02-26-Viralgen-eBlast-700x200-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260602T110000
DTEND;TZID=America/Los_Angeles:20260602T120000
DTSTAMP:20260522T082847Z
CREATED:20260506T180650Z
LAST-MODIFIED:20260522T082847Z
UID:10391-1780398000-1780401600@thebiocalendar.com
SUMMARY:From Complexity to Confidence: Supporting Tech Transfer with a Prefillable Syringe System
DESCRIPTION:This webinar shows how a system-based primary packaging approach—like the West Synchrony™ prefillable syringe system—can streamline tech transfer\, simplify GMP qualification\, and reduce complexity\, cost\, and timelines for injectable drug manufacturing. \nKey Learning Objectives:\n– How injectable technology transfer impacts project timelines\, cost\, and risk when working with a CDMO\n– Where primary packaging decisions intersect with tech transfer activities and why early alignment matters\n– How a system-based approach to prefillable syringe packaging can reduce complexity during tech transfer\n– How the West Synchrony™ S1 prefillable syringe system supports a more streamlined\, turnkey tech transfer with CDMO partners
URL:https://thebiocalendar.com/event/from-complexity-to-confidence-supporting-tech-transfer-with-a-prefillable-syringe-system/
LOCATION:Online webinar
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/05/06-02-26-West-eBlast-700x200-1.png
END:VEVENT
END:VCALENDAR